Nelarabine, sold under the brand names Arranon and Atriance, is a chemotherapy medication used for the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. It is a purine nucleoside analog and functions as a prodrug that is rapidly converted in vivo to 9-beta-D-arabinofuranosylguanine, which is phosphorylated intracellularly to ara-G triphosphate that accumulates in lymphoblasts and inhibits DNA synthesis leading to apoptosis of T-lineage malignant cells. The registered adult regimen typically administers nelarabine intravenously at 1,500 mg per square meter over two hours on days 1, 3 and 5 of a 21-day cycle, with dose adjustments for renal function and prior neurotoxicity. Pharmacokinetics are characterized by rapid plasma conversion to the active metabolite, limited protein binding, and predominantly renal elimination of metabolites. Key clinical considerations include neurotoxicity monitoring, complete blood count surveillance for myelosuppression, and dose modification guidelines for hepatic or renal impairment and concurrent neurotoxic agents.
Parent: Nelarabine
Parent: Nelarabine
For pharmaceutical quality control, nelarabine and its drug substance are characterized by related compounds and degradation products monitored by validated chromatographic methods, with typical specification limits consistent with ICH Q3A and Q3B principles: individual identified related compounds commonly limited to not more than 0.2 to 0.5 percent of the active substance by area percent, and total impurities commonly limited to not more than 1.0 percent, unless a specific impurity requires a tighter control based on toxicity. Typical related compounds and degradants assayed include the active metabolite 9-beta-D-arabinofuranosylguanine, demethylation or dealkylation products, ring-opened hydrolysis products and process-related residuals; residual solvents and elemental impurities are controlled to ICH Q3C and Q3D limits. Specifications should include acceptance criteria, stability-indicating assay validation, forced-degradation profiling to identify potential toxic degradants, and storage conditions to minimize impurity formation.
Common and clinically important adverse effects include neurotoxicity presenting as peripheral neuropathy, somnolence, paresthesia, ataxia and, less commonly, seizures, as well as dose-related myelosuppression with neutropenia, anemia and thrombocytopenia. Other reported effects include nausea, vomiting, fever, fatigue, hepatic transaminase elevations and increased risk of infection. Because neurologic events can be severe and sometimes irreversible, baseline and ongoing neurologic assessment is recommended and dose modification or discontinuation may be required.
Nelarabine is classified as an antineoplastic agent in the purine nucleoside analog class. It is a prodrug of 9-beta-D-arabinofuranosylguanine and is considered an antimetabolite that interferes with DNA synthesis preferentially in T-lineage lymphoblasts.
Response rates vary by disease setting, prior therapies and patient population. In clinical studies of relapsed or refractory T-cell malignancies, objective response rates have varied by trial and indication, with reported ranges roughly in the several tens of percent depending on whether patients had T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma and the extent of prior treatment. Complete remission rates are lower than overall response rates. Efficacy should be interpreted in the context of individual patient factors and compared to alternative salvage or consolidation options by treating clinicians.
The cost of nelarabine varies widely by country, hospital procurement, dose required, number of treatment cycles and insurance coverage. Pricing in practice may result in treatment-course costs that are substantial, commonly amounting to several thousand to tens of thousands of local currency units per course in markets with private or hospital billing. For an accurate estimate obtain quotes from hospital pharmacy, specialty pharmacy providers or the manufacturer and consult insurance or patient assistance programs for coverage and financial support options.
